<DOC>
	<DOCNO>NCT01693445</DOCNO>
	<brief_summary>This study attempt determine feasibility combination Oxaliplatin , Irinotecan , S-1 , maximum tolerate dose recommended dos agent use , preliminarily evaluate antitumor activity untreated patient advance gastrointestinal cancer .</brief_summary>
	<brief_title>S-1 , Oxaliplatin , Irinotecan Advanced Gastrointestinal Cancer</brief_title>
	<detailed_description>Oxaliplatin irinotecan show considerable anti-tumor activity , use combination 5-fluorouracil ( 5-FU ) patient gastrointestinal ( GI ) cancer . Oxaliplatin , irinotecan , 5-FU different mechanism action share toxicity profile . Since synergistic effect , many clinical trial conduct recently evaluate efficacy triplet combination consist oxaliplatin , irinotecan , 5-FU , demonstrated triple combination regimen effective result survival benefit favorable toxicity profile . S-1 capecitabine novel oral fluoropyrimidines different phase III trial show oral agent least active effective 5-FU superior safety profile . Biweekly triple combination S-1 oxaliplatin irinotecan ( OIS ) interest alternative increase convenience simply treatment delivery . In present study , attempt determine feasibility OIS combination , maximum tolerate dose recommended dos agent use , preliminarily evaluate antitumor activity untreated patient advance gastrointestinal cancer .</detailed_description>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically proven recurrent metastatic adenocarcinoma gastrointestinal tract Minimum age 18 year ECOG Performance status 02 Life expectancy &gt; 3 month Presence measurable evaluable disease RECIST Prior adjuvant chemotherapy without S1 , oxaliplatin irinotecan allow 4 week elapse since completion chemotherapy . More 4 week since completion prior radiotherapy ( measurable evaluable lesion outside radiation field ) Adequate organ function Patients must sign informed consent indicate aware investigational nature study keep policy hospital Patients treat previously S1 , oxaliplatin , irinotecan adjuvant chemotherapy . Patients CNS metastasis carcinomatous leptomeningitis neurologic disease . Patients active infection , severe heart disease , uncontrollable hypertension diabetes mellitus , myocardial infarction precede 6 month , pregnancy , breast feeding Any previous concurrent malignancy nonmelanoma skin cancer situ cancer uterine cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Gastrointestinal neoplasm</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>S-1</keyword>
</DOC>